<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057159</url>
  </required_header>
  <id_info>
    <org_study_id>IR902-231</org_study_id>
    <nct_id>NCT02057159</nct_id>
  </id_info>
  <brief_title>A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis</brief_title>
  <official_title>A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Response BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immune Response BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study
      of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo. 200 subjects with Secondary
      Progressive SPMS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:The primary objective is to compare between treatment groups the cumulative number
      of new gadolinium enhancing (Gd+) lesions on brain MRI at weeks 24, 32, 40 and 48 i n
      subjects with secondary progressive MS. Secondary objectives include additional MRI
      measurements, analyses of clinical relapses, measures of neurologic disability, immunologic
      evaluations, and safety.

      Study Design: Multi-center, randomized , double-blind, placebo-controlled , two arm parallel
      design study of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo.

      Subject Population: 200 subjects with Secondary Progressive SPMS MS, with an EDSS score &gt;=
      3.5 , and meeting all inclusion/exclusion criteria, will be enroll in this study. Subjects
      will be randomized equally to NeuroVax™ or I F A

      ,1 0 0 per arm .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI at up to 48 weeks in subjects with secondary progressive MS</measure>
    <time_frame>up to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary MRI measurements objectives include additional MRI measurements, analyses of clinical relapses, measures of neurologic disability, immunologic evaluations, and safety.</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Secondary MRI measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyses of clinical relapses</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Analyses of clinical relapses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of neurologic disability EDSS score</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Measures of neurologic disability EDSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic evaluations</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Immunologic evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Secondary Progress Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>NeuroVax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeuroVax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFA Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IFA Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeuroVax</intervention_name>
    <arm_group_label>NeuroVax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFA Placebo</intervention_name>
    <description>IFA Placebo</description>
    <arm_group_label>IFA Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is between 18 and 50 years of age, inclusive.

          -  Definite MS by the revised McDonald criteria (2005) (Appendix A), with a Secondary
             Progressive course.

          -  Expanded Disability Status Scale (EDSS) &gt;=score 3.5 (Appendix B).

          -  Two or more documented clinical relapses of MS in the preceding 24 months OR one
             documented clinical relapse of MS in the preceding 1 2 months prior to screening .

          -  Laboratory values within the following limits:

               -  Creatinine 1 . 5 x high normal.

               -  Hemoglobin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M Bartholomew, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Immune Response BioPharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard M Bartholomew, Ph.D</last_name>
    <phone>1-858-414-4664</phone>
    <email>Richardmbartholomew@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple Sclerosis Center Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard M Bartholomew, PhD</last_name>
      <phone>1-858-414-4664</phone>
      <email>Richardmbartholomew@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dennis Bourdette, F.A.A.N. M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.immuneresponse.net</url>
    <description>Immune Response BioPharma,Inc.</description>
  </link>
  <link>
    <url>http://www.ohsu.edu</url>
    <description>Oregon Health &amp; Science University</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Progress Multiple Sclerosis</keyword>
  <keyword>SPMS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>NeuroVax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

